Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HEXA | P06865 | 1/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21736903 | 0.82 | KDM4E (0.43) | S1PR4CYP1A2MEN1ALDH1A1LMNA | |
| SCHEMBL1506464 | 0.80 | — | — | |
| SCHEMBL17558629 | 0.80 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL1268660 | 0.78 | GABRP (0.52) | CYP1A2CYP2D6CYP2C9MEN1SLC22A1 | |
| SCHEMBL30381289 | 0.78 | PDCD1 (0.34) | — | |
| SCHEMBL25295311 | 0.78 | PDCD1 (0.34) | — | |
| SCHEMBL31456695 | 0.78 | SIRT2 (0.31) | — | |
| SCHEMBL12250661 | 0.77 | CRHBP (0.39) | S1PR4CYP1A2CYP2D6CYP2C9MEN1 | |
| SCHEMBL19715811 | 0.77 | CCR4 (0.31) | GABRA1GABRB2CCR4 | |
| SCHEMBL29411799 | 0.77 | CCR4 (0.31) | GABRA1GABRB2CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069724-A | Fused ring compounds, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-07 | — | — | US | disclosed |
| CN-116323589-A | Pyridone compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192822-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192588-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-115835911-A | Imidazo [1,2-a ] pyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | PNPO, PDXK, C5 | S1PR4 55/4885CYP1A2 552/4885CYP2D6 479/4885 |
| US-20230279001-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, CNKSR1, UACA | S1PR4 232/4885CYP1A2 534/4885CYP2D6 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.